Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230013/S033

EVOQUE Tricuspid Valve Replacement System

Edwards Lifesciences, LLC · Decision date Oct 21, 2026

MEDTECHLEDGER EXPLANATIONP230013/S033

What did the FDA approve?

The FDA record for P230013/S033, decided October 21, 2026, is a real-time process supplement to the original PMA for the EVOQUE Tricuspid Valve Replacement System. The listed reason is a change to design, components, specifications or material, and the stated purpose is approval of design changes to the guide pin components used in the delivery system. That scope covers delivery-system hardware, not the valve prosthesis itself.

The P230013 identifier ties this action to the parent approval, but a supplement is not a new approval of the whole system, and this entry is not an original PMA. The source reports an approval for changed guide pin components; it does not state what the changes were, why they were made, or what testing supported them. It contains no clinical or performance data, so the decision shows the change was cleared as described, not that safety or effectiveness was independently demonstrated.

The filing text gives no details on guide pin dimensions, materials, compatibility or affected lots; those specifics are absent.

FDA approval order statement

Approval for design changes to the guide pin components used in the delivery system
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Oct 21, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230013/S033
Regulatory pathway
PMA supplement
Product code
NPW
Decision code
APPR
Decision date
Oct 21, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneously Delivered Prostheses and Tricuspid Valves.

Product code
NPW
FDA device class
3

For the original device and its historical approval scope, see PMA P230013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230013 · Original PMA

    Edwards EVOQUE Tricuspid Valve Replacement System

  2. P230013/S033 received

    Application receipt date recorded by FDA.

  3. P230013/S027 · Related supplement

    EVOQUE Tricuspid Valve Replacement System

  4. P230013/S029 · Related supplement

    Edwards EVOQUE Tricuspid Valve Replacement System

  5. P230013/S033 · FDA decision

    Real-Time Process

  6. P230013/S034 · Related supplement

    Edwards EVOQUE Tricuspid Valve Replacement System (9850EV)

Timeline entries are records held by MedtechLedger for P230013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230013

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Edwards Lifesciences, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
One Edwards Way, Irvine, CA, 92614

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records